Plain-English translation of NCT06503146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging scan called 18F-FAPI-74 PET that may help doctors detect cancer better than current standard scans. The scan works by looking for specific markers that appear on cancer cells and the tissue surrounding them. Researchers want to compare this new scan to standard imaging methods (like CT or MRI scans and another type of PET scan called FDG-PET) to see which one is better at finding cancer.
Current cancer imaging methods sometimes miss tumors or can't clearly see how much cancer is present. This medication targets a specific protein found on cancer cells that shows up in more than 90% of many common cancers, and early research suggests it might be better at detecting cancer than existing imaging methods.
You likely qualify if…
You likely don't qualify if…
You will come to the study center at the National Cancer Institute and receive two imaging scans on the same day: the new 18F-FAPI-74 PET scan and a standard FDG-PET scan. Each scan involves receiving an injection of radioactive tracer and then lying still in an imaging machine for about 30–45 minutes total. The scans are painless, and you should be able to go home the same day. If you are able to have children, you'll need to use birth control for 2 months after the imaging scans, and if you are breastfeeding, you'll need to stop for 2 months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States